Mouse SAP/PTX2 ELISA Kit
CNY 5,000.00
货期*
3周
规格
Cited in 1 publication. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
Specifications
Product Data | |
Description | Mouse SAP/PTX2 ELISA Kit |
Size | 1 x 96 wells |
Assay Type | Sandwich ELISA kit of Quantitative Detection for Mouse SAP/PTX2 |
Assay Length | 3.5 hours incubations; 1 hour washing and analyzing samples |
Signal | Colorimetric |
Curve Range | 1.56ng/ml-100ng/ml |
Sample Type | Cell culture supernates, serum and plasma(heparin, EDTA). |
Sample Volume | 100 ul |
Specificity | This kit is used for quantitative detection of mouse SAP |
Sensitivity | <50pg/ml |
Reactivity | Mouse |
Cross Reactivity | There is no detectable cross-reactivity with other relevant proteins. |
Interference | No significant interference observed with available related molecules. |
Components |
|
Background | Amyloid P component, serum(SAP), also known as PTX2 or APCS, is the identical serum form of amyloid P component(AP), a 25kDa pentameric protein first identified as the pentagonal constituent of in vivo pathological deposits called "amyloid". It belongs to the pentraxins family, characterised by calcium dependent ligand binding and distinctive flattened beta-jellyroll structure similar to that of the legume lectins. This gene is mapped to 1q23.2. The binding of the encoded protein to proteins in the pathological amyloid cross-beta fold suggests its possible role as a chaperone. This protein is also thought to control the degradation of chromatin. It has been demonstrated that this protein binds to apoptotic cells at an early stage, which raises the possibility that it is involved in dealing with apoptotic cells in vivo. |
Gene Symbol | Apcs |
Citations (1)
The use of this Assay Kits has been cited in the following citations: |
---|
Immunosuppressive Potential of Activated Human Amniotic Cells in an Experimental Murine Model of Skin Allo- and Xenotransplantation
,null,
Frontiers in Medicine
,PubMed ID 34631739
[Apcs]
|
Documents
Product Manuals |
Customer
Reviews
Loading...